|
|
Drug Development |

|
ReceptoPharm is developing proprietary
therapeutic protein products for the treatment of neurological,
viral and and autoimmune disorders. |
»
Learn More |
|
|
|
CRO Services |
ReceptoPharm offers a full range of contract
research services catering to small and start-up biotech companies. |
» Learn More |
|
|
|
ReceptoPharm maintains collaborative and
research relationships with a number of
noted academic researchers associated with
the National Institutes of Health (NIH),
Harvard University, Massachusetts General
Hospital, Yale University, Stanford University,
Baylor College of Medicine, the University
of Saskatchewan, Soochow University, the
University of Dundee and USAMRIID of
the Department of Defense.
Clinical development links have been established
not only within the US but also within China,
the U.K., and Canada to augment ReceptoPharm's
internal research and development efforts.
All the researchers involved are recognized
experts in their respective fields, have
proven credentials as well as histories
of successful grant applications, and recognition
from academia and government agencies administering
these research programs. Some of these researchers
have become members of ReceptoPharm's Scientific
Board of Advisors.
Dorothy Bray, Ph.D., is
a Clinical/Research Development Consultant
with nine years experience working in HIV
research and development with GlaxoSmithKline
plc (previously Glaxo Wellcome), the largest
provider of HIV antiretroviral drugs with
an estimated 40% global market share. Dr.
Bray has significant expertise in clinical
development and market positioning for novel
drugs. Her key skills include broad scientific
and regulatory knowledge, strategic planning,
and commercial awareness. Dr. Bray had global
responsibility for clinical trials program
for her most recent position as Director,
Clinical Development HIV, GlaxoSmithKline,
UK. She holds a Ph.D. from the School of
Pharmacy, University of London; 1987 and
an MSc (1st in Class) in Biology, The Jagiellonian
University of Cracow, Poland, 1979.
Zouhair M. Atassi, Ph.D., D.Sc.,
is currently a Professor of Biochemistry
and Professor of Immunology at Baylor College
of Medicine in Houston, Texas. He has many
years of experience working with neurotoxins
in the field of neurochemistry and immunology.
A highly published scientist, he has authored
over 400 papers. He is charged with assessing
RPI-78 and RPI-MN in animal models of Myasthenia
gravis and EAE.
Zheng-Hong Qin, MD, Ph.D.,
divides his time between Harvard University/Massachusetts
General Hospital in Boston and Soochow University
in Suzhou, China, where he conducts research
on neurological disorders. His Chinese medical
education has provided him with an important
background on the use of anticholinergic
peptides in medicine. He acts as a mediator
in connection with studies conducted at
Soochow University. Dr. Qin also conducts
research for ReceptoPharm in such areas
as pain and cancer in his research laboratories
at Soochow University.
ReceptoPharm, Inc. has entered into agreements
with consultants. All these specialists
have indicated a willingness to join our
Scientific Advisory Board in the future.
Thomas L. Lentz, MD, is
currently Dean of Admissions at Yale University
having taken this position fulltime. Prior
to this post he was head of the Department
of Cell Biology where he originated the
theory that the Rabies virus employed the
nicotinic receptor as the entry portal.
Dr. Lentz and his groups published extensively
on the subject. He has agreed to act as
a consultant to ReceptoPharm with the option
of joining the Scientific Advisory Board.
|
|
|
E-Alerts
|
Signup to receive news and announcements
from ReceptoPharm and Nutra Pharma: |
|
|
|
|
|
|